

In the Claims

1 (currently amended). A composition comprising a tissue glue and, ~~immobilized in the glue,~~ in particulate form, a radiotherapeutic agent or an agent convertible to a radiotherapeutic, wherein ~~the said agent is~~ mediates localized radiotherapeutic activity when immobilized in the glue ~~for a period of time sufficient for a radiotherapeutic effect.~~

Claims 2-3 (canceled)

4 (original). The composition according to claim 1, which additionally comprises a material that inhibits degradation of the glue.

5 (original). The composition according to claim 1, wherein the agent is in the form of a chelate holding a radioactive atom.

6 (original). The composition according to claim 1, wherein the agent is a ferrite.

7 (original). The composition according to claim 1, which additionally comprises a radiation sensitizer capable of leaching out and augmenting the local radiotherapeutic effect.

8 (original). The composition according to claim 1, which additionally comprises a growth factor or other substance that mitigates the anti-wound-healing effect of radiation.

9 (original). The composition according to claim 1, wherein the agent comprises a zinc-substituted yttrium ferrite, or a  $^{56}\text{Fe}$ -enriched ferrite.

10 (original). The composition according to claim 1, wherein the agent comprises  $^{103}\text{Pd}$  or  $^{90}\text{Y}$ .

11 (original). A method for the radiotherapy of a tumor, which comprises applying to the tumor an effective amount of a composition as defined in claim 1.

12 (original). The method of claim 11, wherein the radiotherapy of a tumor comprises brachytherapy.

13 (previously amended). The composition according to claim 1, further comprising an antibody, and wherein the tissue glue is a fibrinogen tissue glue.

14 (original). The composition according to claim 13, wherein the particulate radionuclide is a  $\beta$ -emitting ferrite.

15 (original). The composition according to claim 13, wherein the particulate radionuclide is coupled to the antibody.

16 (original). The composition according to claim 15, wherein the antibody is a nerve adhesion molecule.

17 (previously amended). A method for making a radiotherapeutic composition according to claim 13, which comprises:

- (a) preparing a particulate radionuclide; and
- (b) mixing the particulate radionuclide with the fibrinogen tissue glue and the antibody.

18 (previously amended). A method of using a radiotherapeutic composition according to claim 13, which comprises applying the composition directly to tumor tissue.

19 (original). A method of radiation synovectomy which comprises administering an effective amount of a composition of claim 1 to a patient to be treated.

20 (original). A method of radiotherapy in the treatment of arterio-venous malformations in a blood vessel which comprises applying to the blood vessel a composition as defined in claim 1.

21 (currently amended). A composition comprising a tissue glue and, ~~immobilized in the glue,~~ in particulate form, a radiotherapeutic ferrite or a ferrite convertible to a radiotherapeutic, wherein the ferrite ~~is~~ mediates localized radiotherapeutic activity when immobilized in the glue ~~for a period of time sufficient for a radiotherapeutic effect.~~

22 (previously presented). The composition according to claim 21, wherein the ferrite is a  $\beta$ -emitting ferrite.

23 (currently amended). A composition comprising a tissue glue and, ~~immobilized in the glue,~~ in particulate form, a radiotherapeutic agent or an agent convertible to a radiotherapeutic, wherein the agent comprises a zinc substituted yttrium ferrite or a  $^{56}\text{Fe}$ -enriched ferrite, wherein the ~~said agent is~~ mediates localized radiotherapeutic activity when immobilized in the glue ~~for a period of time sufficient for a radiotherapeutic effect.~~

24 (currently amended). A composition comprising a tissue glue and, ~~immobilized in the glue,~~ in particulate form, a radiotherapeutic agent or an agent convertible to a radiotherapeutic, wherein the agent is a ferrite comprising  $^{103}\text{Pd}$  or  $^{90}\text{Y}$ , and wherein ~~the said agent is~~ mediates localized radiotherapeutic activity when immobilized in the glue ~~for a period of time sufficient for a radiotherapeutic effect.~~